Birnbaum D, Gaudray P
U.119, Marseille, France.
Bull Cancer. 1989;76(7):677-87.
Recent developments in molecular oncology have permitted the definition of alterations in proto-oncogenes (ras, myc, neu and hst/int.2) and anti-oncogenes (Rb.1) in human breast carcinomas. Detection of these abnormalities could be of prognostic interest. However, this remains controversial.
分子肿瘤学的最新进展使得人们能够明确人类乳腺癌中原癌基因（ras、myc、neu和hst/int.2）和抗癌基因（Rb.1）的改变。检测这些异常情况可能具有预后意义。然而，这一点仍存在争议。
